Estudio comparativo de la absorción neta de calcio de dos formulaciones distintas de carbonato de calcio en mujeres posmenopáusicas / Comparative study of net calcium absorption of two different pharma¬ceutical formulations of calcium carbonate in posmenopausal women

La suplementación con calcio reduciría, sola o asociada a otra medicación para osteoporosis, la pérdida de masa ósea y el riesgo de fracturas. Sin embargo, su tasa de adherencia es baja debido a la poca tolerancia. Objetivo: comparar la tasa de absorción neta de calcio entre dos formulaciones distintas de carbonato de calcio (500 mg): comprimidos vs. mousse. Material y métodos: 11 pruebas fueron realizadas en mujeres posmenopáusicas de 58,9±3 años. El diseño fue exploratorio abierto, aleatorizado, prospectivo cruzado de fase 4. Intervención: las participantes fueron aleatorizadas en dos grupos para recibir las dos formulaciones previa suplementación con vitamina D3. La tasa de absorción neta de calcio fue estudiada por la prueba de inhibición de hormona paratiroidea (PTH). Se obtuvieron muestras de sangre: basal y en la 1a, 2a y 3a hora posadministración del calcio asignado, y de orina de 2 horas basal y al final de la prueba. Determinaciones bioquímicas: calcio, fósforo, albúmina, 25-hidroxivitamina D y hormona paratiroidea intacta y calciuria. Análisis estadístico: método de los trapecios para calcular el área bajo la curva (AUC) de la concentración de calcio en el tiempo (R Development Core Team (2008). http://www.Rp-project.org) y Anova con dos términos de error para evaluar el efecto secuencia, período y formulación. Resultados: la mayor inhibición de PTH se observó a dos horas de la toma de ambas formulaciones (comprimidos -39,2% vs. mousse -38,0%; p=ns), con similar AUC0-3 h (comprimidos 3,35; IC 95%: 3,32; 3,37 vs. mousse 3,36; IC 95%: 3,33; 3,38). Cuando analizamos tolerancia y preferencias no se observaron diferencias estadísticamente significativas entre ambas formulaciones. Conclusión: el carbonato de calcio en mousse mostró similar tasa de absorción intestinal, preferencia y tolerancia gastrointestinal que en comprimido. (AU)

Calcium supplementation, administered alone or in combination with a specific medication for osteoporosis, would reduce bone mass loss and fracture risk in postmenopausal women. However, the adherence rate to calcium supplements is low, mainly due to low tolerance. Objective: comparisson of net calcium absorption rate between two different pharmaceutical formulations of calcium carbonate (PFCa) in postmenopausal women. Materials and Methods: 11 tests were performed in postmenopausal women aged 58.9±3 yrs. Design: Comparative, randomized, prospective, open-label exploratory crossover study of calcium mousse versus calcium pills. Intervention: Participants were randomized in 2 groups to receive the 2 different PFCa (500mg): pills vs. mousse, with previous vitamin D3 supplementation. The parathyroid hormone (PTH) inhibition test and the area-under-thecurve (AUC) of calcium were analyzed. Blood samples were taken at baseline and 1, 2 and 3 hrs after intake of the assigned PFCa. Urine samples (2hs) were obtained at -baseline, after 2hs of PFCa intake and at the end of the test. Biochemical Determinations: Serum: calcium, phosphorus, albumin, 25-hydroxyvitamin D, and intact PTH. In urine: calcium. Statistical Analysis: The trapezoid rule was applied to assess AUC in time (R Development Core Team (2008). http://www.Rp-project.org). An ANOVA model with 2 error terms was used to assess the effect of sequence, period, and formulation. Results: The highest inhibition PTH rates were observed after 2 hrs of PFCa (pills -39.2% vs. mousse -38.0%; p=ns). The AUC0-3hrs for both PFCa was similar (pills 3.35; 95%CI: 3.32; 3.37 vs. mousse 3.36; 95%CI: 3.33; 3.38). No statistically significant differences were observed when we analyze tolerance and predilection. Conclusion: The calcium carbonate in mousse showed an adequate rate of intestinal absorption, similarly predilection and gastrointestinal tolerance than the pill presentation. (AU)

Preeclampsia prevention: a case-control study nested in a cohort / La prevención de la preeclampsia: un estudio de casos y controles anidado en una cohorte

Introduction: Preeclampsia is the main complication of pregnancy in developing countries. Calcium starting at 14 weeks of pregnancy is indicated to prevent the disease. Recent advances in prevention of preeclampsia endorse the addition of conjugated linoleic acid. Objective: To estimate the protective effect from calcium alone, compared to calcium plus conjugated linoleic acid in nulliparous women at risk of preeclampsia. Methods: A case-control design nested in the cohort of nulliparous women attending antenatal care from 2010 to 2014. The clinical histories of 387 cases of preeclampsia were compared with 1,054 normotensive controls. The exposure was prescriptions for calcium alone, the first period, or calcium plus conjugated linoleic acid, the second period, from 12 to 16 weeks of gestational age to labor. Confounding variables were controlled, allowing only nulliparous women into the study and stratifying by age, education and ethnic group. Results: The average age was 26.4 yrs old (range= 13-45), 85% from mixed ethnic backgrounds and with high school education. There were no differences between women who received calcium carbonate and those who did not (OR= 0.96; 95% CI= 0.73-1.27). The group of adolescents (13 to 18 yrs old) in the calcium plus conjugated linoleic acid was protected for preeclampsia (OR= 0.00; 95% CI= 0.00-0.44) independent of the confounder variables. Conclusions: 1. Calcium supplementation during pregnancy did not have preventive effects on preeclampsia. 2. Calcium plus Conjugated Linoleic acid provided to adolescents was observed to have preventive effect on Preeclampsia.

Introducción: La preeclampsia es la principal causa de mortalidad materna y bajo peso al nacer en países en vías de desarrollo. Empezar la suplementación de calcio en la semana 14 de gestación es indicada para prevenir la enfermedad. Recientes avances en prevención de preeclampsia han sugerido la suplementación de calcio y la combinación de calcio con ácido linoleico conjugado. Objetivo: Estimar el efecto protector de la suplementación de calcio (CC), comparado con la suplementación de calcio más ácido linoleico conjugado (CC+ALC) en mujeres embarazadas primigravidas con relación al desarrollo de preeclampsia. Métodos: Se realizó un estudio de casos y controles anidado en una cohorte retrospectiva de mujeres embarazadas primigravidas que asistieron al programa de control prenatal entre el año 2010 hasta el años 2014. La historia clínica de 387 casos de preeclampsia fueron comparadas con 1,054 controles en pacientes embarazadas primigestantes, normotensas. Las gestantes expuestas fueron consideradas como aquellas gestantes que recibieron solo calcio, en el primer periodo de evaluación, o calcio más ácido linoleico conjugado, segundo periodo de evaluación, desde las semanas 12 a la 16 del embarazo. Los posibles factores de confusión se controlaron admitiendo solo las primigestantes y estratificando, por edad, educación y grupo étnico de la paciente. Resultados: La edad promedio de las pacientes fue de 26.4 años (rango= 13-45), 85% con etnia mestiza y educación secundaria completa. La exposición a CC+ALC tuvo un efecto protector en las adolescentes (13 a 18 años) (OR= 0.00, IC 95%= 0.00-0.44; p= 0.005), mientras que la exposición a CC no modificó la incidencia de preeclampsia (OR= 0.96, IC 95%= 0.73-1.27; p= 0.82). Conclusiones: 1. La suplementación de solo calcio durante el embarazo no tuvo efecto preventivo para la preeclampsia, 2. La suplementación con calcio y ácido linoleico conjugado previno la aparición de preeclampsia en adolescentes.

SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE? / HIPERPARATIREOIDISMO SECUNDÁRIO APÓS CIRURGIA BARIÁTRICA: TRATAR COM CARBONATO OU CITRATO DE CÁLCIO?

Background:Bariatric surgery, especially Roux-en-Y gastric bypass, can cause serious nutritional complications arising from poor absorption of essential nutrients. Secondary hyperparathyroidism is one such complications that leads to increased parathyroid hormone levels due to a decrease in calcium and vitamin D, which may compromise bone health.Aim: To compare calcium carbonate and calcium citrate in the treatment of secondary hyperparathyroidism.Method: Patients were selected on the basis of their abnormal biochemical test and treatment was randomly done with citrate or calcium carbonate.Results: After 60 days of supplementation, biochemical tests were repeated, showing improvement in both groups.Conclusion: Supplementation with calcium (citrate or carbonate) and vitamin D is recommended after surgery for prevention of secondary hyperparathyroidism.

Racional:A cirurgia bariátrica, especialmente a gastroplastia em Y-de-Roux, pode causar complicações nutricionais importantes que derivam da má absorção de nutrientes essenciais. O hiperparatireoidismo secundário é uma delas que cursa com o aumento do hormônio da paratireoide e consequente diminuição de cálcio e vitamina D, o que pode comprometer a saúde óssea.Objetivo: Comparar o tratamento do hiperparatireoidismo secundário com o uso de carbonato e citrato de cálcio.Métodos: Os pacientes foram selecionados a partir de seus exames bioquímicos alterados e o tratamento foi sugerido aleatoriamente com citrato ou carbonato de cálcio.Resultados: Após 60 dias de suplementação foram reavaliados os exames bioquímicos e percebeu-se melhora em ambos os grupos, tanto com citrato como com carbonato de cálcio.Conclusão: Recomenda-se o uso de suplementação de cálcio (citrato ou carbonato) e vitamina D após a operação para prevenção do hiperparatireoidismo secundário.

Tratamiento de la hipersensibilidad dentinaria post terapia periodontal, mediante el uso de dos dentífricos desensibilizantes / Dentin hypersensitivity treatment post periodontal therapy, using two desensitizing dentifrices

Objetivo: El objetivo de este estudio fue evaluar y comparar la eficacia en la reducción de la hipersensibilidad dentinaria posterior a la terapia periodontal utilizando dentífricos que contienen arginina al 8 por ciento - carbonato de calcio versus acetato de estroncio al 8 por ciento, tras una y tres semanas de uso de las pastas dentales. Materiales y Método: Estudio clínico, aleatorio, ciego y controlado con dos grupos paralelos, y tres semanas de seguimiento, en el cual el universo de trabajo fue de 20 pacientes con diagnóstico de periodontitis crónica generalizada leve o moderada y que hayan presentado hipersensibilidad dentinaria posterior a la terapia periodontal no quirúrgica en al menos un canino y/o premolar, y asociado a recesión gingival. Los pacientes fueron seleccionados aleatoriamente y se distribuyeron al azar en cada grupo de pastas dentales y fueron evaluados tras una y tres semanas de uso de los dentífricos. Se les aplicó aire proveniente de la jeringa triple del equipo dental en la zona cervical con hipersensibilidad, estandarizando la técnica. La cuantificación del dolor se realizó a través de la Escala Visual Análoga (EVA). Resultados: No hubo diferencia estadísticamente significativa entre el uso de los dentífricos que contienen arginina 8 por ciento - carbonato de calcio versus acetato de estroncio al 8 por ciento para la reducción de la hipersensibilidad dentinaria tras una y tres semanas de uso de las pastas dentales. Existió diferencia estadísticamente significativa en la reducción del dolor con el uso de ambos dentríficos a la primera y tercera semana de medición.

Aim: The aim of this clinical study was to evaluate and to compare the efficacy in reducing the dentin hypersensitivity after periodontal therapy using dentifrices which contain 8 percent arginine, calcium carbonate versus 8 percent strontium acetate, after one and three weeks of use of the dentifrices. Methods: A three-week clinical study with 20 subjects with diagnosis of slight to moderate chronic periodontitis with dental hypersensitivity after periodontal therapy, and presence of gingival recession in canines and/or premolars. Patients were randomly selected and assigned to each group and toothpastes were evaluated after one and three weeks of use. Air from a triple syringe was applied into the cervical area with hypersensitivity. The quantification of pain was performed using the Visual Analogue Scale (VAS). Results: There was not statistically significant difference between the use of the dentifrices which contain 8 percent arginine, calcium carbonate versus 8 percent strontium acetate in reducing dentin hypersensitivity after one and three weeks of use of the dentifrices. Nevertheless, there was a statistically significant difference in the reduction of pain using both dentifrices in the first and third week of measurement.

A Case of Isolated Small Intestinal Wall Calcification on Patient with Continuous Ambulatory Peritoneal Dialysis / 대한소화기학회지

The metastatic calcification is defined as the deposition of calcium salt in normal tissue with an abnormal serum biochemical environment, such as chronic kidney disease, hyperparathyroidism, and hypercalcemia related with malignancy. Although the metastatic calcification can develop in any organs and tissues, presenting its symptoms and complications are rare. Thus a few cases have been reported. This case shows the metastatic calcification of the small intestine without any peritoneal and mesenteric vascular calcification which was early diagnosed by computed tomography and mesenteric angiography in a patient with abdominal pain, receiving continuous ambulatory peritoneal dialysis due to end stage renal disease. The clinician should early consider the metastatic calcification as differential diagnosis when unidentified calcifications are noted in simple abdominal X-ray such as in the present case, and promptly confirm it by using appropriate diagnostic tests in order to prevent its complications and progression.

Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia / Análisis de costo-efectividad de la administración postoperatoria de Vitamina D y calcio después de tiroidectomía para la prevención de la hipo calcemia

Objective Hypocalcaemia is a frequently arising complication following total thyroidectomy. Routine postoperative prophylactic administration of vitamin D or metabolites and calcium reduce the incidence of symptomatic hypocalcaemia; this article reports evaluating its cost-effectiveness in Colombia. Methods Meta-analysis was used for comparing the administration of vitamin D or metabolites to oral calcium or no treatment at all in patients following total thyroidectomy and a cost-effectiveness analysis was designed based on a decision-tree model with local costs. Results The OR value for the comparison between calcitriol and calcium compared to no treatment and to exclusive calcium treatment groups was 0.32 (0.13-0.79 95 %CI) and 0.31 (0.14-0.70 95 %CI), respectively. The most cost-effective strategy was vitamin D or metabolites and calcium administration, having a US $0.05 incremental cost-effectiveness ratio. Conclusion Prophylactic treatment of hypocalcaemia with vitamin D or metabolites + calcium or calcium alone is a cost-effective strategy.

Objetivos La hipo calcemia es la complicación más frecuente después de tiroidectomía. La administración profiláctica de vitamina D o metabolitos y calcio reduce la incidencia de hipocalcémia sintomática. Se evalúa su costo-efectividad en Colombia. Materiales y métodos Utilizamos la información de un meta-análisis que comparó la administración de vitamina D o metabolitos contra calcio no tratamiento en pacientes llevados a tiroidectomía total y diseñamos un análisis de costo-efectividad basados en un modelos de decisiones con costos locales. Resultados El valor del OR para la comparación entre calcitriol y calcio comparado con no tratamiento o calcio exclusivo fue de 0.32 (95 % IC, 0.13- 0.79) y 0.31 (95 % IC, 0.14-0.70), respectivamente. La estrategia más costo-efectiva fue la administración de vitamina D o metabolitos y calcio, con una relación de costo-efectividad incremental de US $0.05. Conclusiones El tratamiento profiláctico de la hipo calcemia con vitamina D o metabolitos y calcio o calcio exclusivo después de tiroidectomía total es una estrategia costo-efectiva.

Efecto de la arginina 8 por ciento-carbonato de calcio y del fluoruro de sodio al 5 por ciento en la reducción de la hipersensibilidad dentinaria post terapia periodontal: ensayo clínico / Effect of 8 percent arginine, calcium carbonate and 5 percent sodium fluoride on the reduction of the dentine hipersensitivity post periodontal therapy: clinical trial

Objetivo: El objetivo de este estudio clínico fue evaluar y comparar la eficacia en la reducción de la hipersensibilidad dentinaria de la arginina al 8 por ciento-carbonato de calcio, monofluorfosfato (1.450 ppm) en comparación con un grupo control tratado en base a un barniz de flúor (22.600 ppm) y un dentífrico fluorado (1.450 ppm), 3 veces al día durante un minuto, en pacientes con hipersensibilidad radicular en forma inmediata a la terapia periodontal mecánica (medición basal) y a las 4 semanas respectivamente. Materiales y Método: Estudio clínico aleatorizado de grupos paralelos, con 4 semanas de seguimiento, en el cual se reclutaron 20 pacientes con diagnóstico de periodontitis crónica leve a moderada, en tratamiento periodontal mecánico con presencia de recesiones gingivales a nivel de incisivos, caninos o premolares. A todos ellos, previa firma de consentimiento informado y en forma inmediata a los pulidos radiculares, se les aplicó el test térmico de chorro de aire con la jeringa de aire de la unidad dental a nivel de las recesiones gingivales con hipersensibilidad. La molestia o dolor fue determinado mediante la utilización de una escala visual análoga, realizada en forma inmediata a los pulidos radiculares (medición basal). Los pacientes fueron aleatoriamente asignados a uno de los siguientes grupos: grupo control, se les aplicó barniz de flúor (22.600 ppm) en todas las recesiones gingivales y se les indicó un dentífrico fluorado (1.450 ppm); grupo experimental, a quienes se les aplicó pasta tópica de arginina y carbonato de calcio (8 por ciento) a nivel de las recesiones gingivales, complementado con el uso de un dentífrico cuyo componente activo es la arginina al 8 por ciento-carbonato de calcio. Todos los pacientes fueron evaluados 4 semanas posterior a la aplicación y utilización domestica de los agentes des-sensibilizantes por un único examinador. Resultados: Ambos grupos experimentaron una disminución en la sensibilidad dentinaria, sin...

Aim: The aim of this clinical study was to evaluate and to compare the efficacy in reducing the dentine hypersensitivity of an 8 percent arginine, calcium carbonate, 1.450 ppm sodium monofluorophosphate dentifrice with topical application and twice-daily brushing, with a negative control toothpaste containing calcium carbonate and 1.450 ppm fluoride as MFP, after periodontal treatment (baseline) and four weeks respectively. Methods: A four-week clinical study with 20 subjects with diagnosis of slight to moderate chronic periodontitis under mechanical periodontal treatment and presence of gingival recessions in incisors, canines or premolars, stratified based on baseline tooth sensitivity. Subjects brushed with either a 1.450 ppm fluoride dentifrice or a marketed 8 percent arginine calcium carbonate dentifrice twice daily for approximately one minute. At screening, baseline and weeks four, subjects' tooth sensitivity was determined through both evaporative (Schiff and Visual Analogue Scale [VAS]). The same examiner throughout the study performed subject assessments using each stimulus. Results: Both subject groups exhibited significant reductions from baseline to four weeks in dentine hypersensitivity. However, patients who received 8 percent arginine calcium carbonate therapy, exhibited a greater reduction, with a 60 percent of individuals lacking of pain and with a final median of 0 in comparison with the 5 percent fluoride varnish and fluoride toothpaste group in which a 100 percent of subjects felt some degree of pain, presenting a final medium VAS scale of 2.

Effect of short-term ornithine alpha-ketoglutarate pretreatment on intestinal ischemia-reperfusion in rats / Efeitos do pré-tratamento em curto prazo com ornitina alfa-cetoglutarato na isquemia-reperfusão intestinal em ratos

PURPOSE: To investigate the effects of preventive enteral administration of ornithine alpha-ketoglutarate (OKG) in an ischemia-reperfusion rat model. METHODS: Sixty rats were randomized into five groups (G1-G5, n = 12). Each group was divided into two subgroups (n = 6) and treated with calcium carbonate (CaCa) or OKG by gavage. Thirty minutes later, the animals were anesthetized with xylazine 15mg + ketamine 1mg ip and subjected to laparotomy. G1-G3 rats served as controls. Rats in groups G4 and G5 were subjected to ischemia for 30 minutes. Ischemia was achieved by clamping the small intestine and its mesentery, delimiting a segment of bowel 5 cm long and 5 cm apart from the ileocecal valve. In addition, G5 rats underwent reperfusion for 30 minutes. Blood samples were collected at the end of the laparotomy (G1), after 30 minutes (G2, G4) and 60 minutes (G3, G5) to determine concentrations of metabolites (pyruvate, lactate), creatine phosphokinase (CPK), thiobarbituric acid reactive substances (TBARS) and glutathione (GSH). RESULTS: There was a significant decrease in tissue pyruvate and lactate and plasma CPK levels in OKG-treated rats at the end of reperfusion period. GSH levels did not change significantly in ischemia and reperfusion groups. However, TBARS levels increased significantly (p<0.05) in tissue samples in OKG-treated rats subjected to ischemia for 30 minutes. CONCLUSION: Short-term pretreatment with OKG before induction of I/R decreases tissue damage, increases pyruvate utilization for energy production in the Krebs cycle and does not attenuate the oxidative stress in this animal model.

OBJETIVO: Investigar os efeitos da administração enteral preventiva de ornitina alfa-cetoglutarato (OKG) em modelo de isquemia-reperfusão no rato. MÉTODOS: Sessenta ratos foram randomizados em cinco grupos (G1-G5, n=12). Cada grupo foi redistribuído em dois subgrupos (n=6) e tratado com carbonato de cálcio (CaCa) ou OKG por gavagem. Trinta minutos mais tarde, os animais foram anestesiados com xilazina 1mg+cetamina 15mg i.p. e submetidos à laparotomia. Os ratos dos grupos G4-G5 foram submetidos à isquemia por 30 minutos. A isquemia foi obtida por pinçamento do intestino delgado, delimitando um segmento com 5 cm de comprimento e distando 5 cm da válvula ileocecal. O grupo G5 foi submetido à reperfusão por 30 minutos. Amostras de sangue foram coletadas no final da laparotomia (G1), após 30 minutos (G2, G4) e 60 minutos (G3, G5) para determinação das concentrações de metabolitos (piruvato, lactato), creatinofosfoquinase (CPK), substâncias reativas ao ácido tiobarbitúrico (TBARS) e glutationa (GSH). RESULTADOS: Observou-se redução significante (p<0,05) das concentrações de piruvato e lactato, teciduais e CPK plasmático em ratos tratados com OKG, no final do período de reperfusão. Não houve alteração significante nos níveis plasmáticos e teciduais de GSH. Entretanto os níveis de TBARS aumentaram significativamente (p<0,05) em amostras de tecido de ratos tratados com OKG submetido à isquemia por 30 minutos. CONCLUSÃO: o pré-tratamento em curto prazo com OKG antes da indução da I/R diminui a lesão tecidual, aumenta a utilização de piruvato para produção de energia no ciclo de Krebs, mas não atenua o estresse oxidativo neste modelo animal.

Autosomal Dominant Hypocalcemia Caused by an Activating Mutation of the Calcium-Sensing Receptor Gene: The First Case Report in Korea

Hypoparathyroidism is an abnormality of calcium metabolism characterized by low serum levels of parathyroid hormone in spite of hypocalcemia. The causes of hypoparathyroidism are numerous. Activating mutations in the calcium-sensing receptor (CaSR) gene are well-known causes of familial isolated hypoparathyroidism, also known as autosomal dominant hypocalcemia (ADH). Here we describe members of a Korean family with a heterozygous Pro221Leu mutation causing ADH. This case is the first report in Korea.

The efficacy of a herbal-based toothpaste in the control of plaque and gingivitis: A clinico-biochemical study.

Objective: A double-blinded controlled clinical trial with parallel groups was designed to investigate the effectiveness of a herbal-based toothpaste in the control of plaque and gingivitis as compared with a conventional dentifrice. The efficacy of Colgate Herbal over Colgate tooth paste was assessed in this study. Materials and Methods: Thirty subjects with gingivitis participated in the study. All participants had at least 20 natural teeth with no probing depths greater than 3 mm and a plaque index score of 2 or more at baseline. At baseline, the clinical parameters like gingival index, plaque index and salivary pH were estimated. Paired t-test was used to compare the difference within the groups and unpaired t-test was used to compare the difference between the groups at baseline and on the 30 th day. Results: At the end of the study, there were statistically significant reductions in the gingival index and the plaque index scores within the test group. However, there were no statistically significant differences between the test and the control groups. The salivary pH changes were not statistically significant in the test group but were displaced more toward the acidic range in the control group. Conclusion: It was however concluded that the herbal-based toothpaste was as effective as the conventionally formulated dentifrice in the control of plaque and gingivitis.

Doença periodontal em portadores de osteopenia/osteoporose - revisão de literatura / Periodontal disease in patients with osteopenia/osteoporosis - Review of literature

Esta revisão da literatura buscou confirmara hipótese que osteopenia/osteoporose é um fator de risco para doença periodontal. Uma vez que a inflamação, resultante da presença de bactérias patogênicas no periodonto, tem como resultado a reabsorção óssea, supõem-se que na presença de baixa densidade óssea a doença periodontal será mais severa. No entanto, foi observado que os autores não seguem padrões em relação às pesquisas que envolvem este tema. Número das amostras, que em alguns trabalhos é muito pequeno; idade das pessoas examinadas; métodos para obtenção da densidade óssea; parâmetros para os exames do periodonto, são fatores que dificultam a comparação dos dados obtidos em cada trabalho. É necessário uniformizar os exames e suas interpretações. Um número crescente de estudos aponta para o fato de que osteopenia/osteoporose é um fator agravante da doença periodontal. A forma mais indicada de pesquisa são os estudos longitudinais. Estudos envolvendo terapia de reposição hormonal e/ou ingestão de cálcio e vitamina D apontam para a melhora nos parâmetros de saúde periodontal. É prudente aguardar novas investigações longitudinais para definir um protocolo de conduta para pacientes com osteopenia/ osteoporose portadores de doença periodontal.

Qualidade de silagens de sorgo com aditivos / Quality of sorghum silages with additives

Um delineamento inteiramente ao acaso, com três repetições, foi utilizado para avaliar os efeitos da adição de 0,5 por cento de uréia, de 0,5 por cento de carbonato de cálcio (CaCO3), de 0,5 por cento de uréia mais 0,5 por cento de CaCO3 e de inoculante bacteriano sobre o pH, teores de matéria seca (MS), proteína bruta (PB), fibra em detergente neutro (FDN), fibra em detergente ácido (FDA), hemicelulose, celulose, lignina, carboidratos solúveis, ácido lático e ácido acético sobre a digestibilidade in vitro da matéria seca (DIVMS) de silagens de quatro híbridos de sorgo (BR700, BR701, BR601 e AG2002). Os híbridos ensilados sem a adição de aditivos constituíram o grupo-controle. De cada genótipo foram coletadas três amostras do material original (MOR). Foram utilizados 60 silos de PVC com 10cm de diâmetro interno e 50cm de comprimento, sendo três por tratamento. A abertura dos silos ocorreu depois de 56 dias de fermentação. As silagens contendo CaCO3 e inoculante bacteriano apresentaram, em geral, características muito semelhantes às do controle. A adição de uréia e de uréia mais CaCO3 às silagens resultou em aumento (P<0,05) nos teores de PB. A adição conjunta de uréia e CaCO3 não propiciou aumento (P<0,05) superior ao obtido nas silagens contendo apenas uréia. Uréia pura, como aditivo, pode ser recomendada na ensilagem dos híbridos BR700, BR601 e AG2002.

Osteoporose na infância e adolescência. (Editorial) / Osteoporosis in childhood and adolescence. (Editorial)

A osteoporose progressivamente passou a constituir tema de interesse pediátrico. De um lado, foi reconhecido que a densidade mineral óssea (DMO) de indivíduos adultos e idosos depende do pico de massa óssea adquirido até o final da segunda década de vida.Sob este ângulo, o pediatra tem, portanto, a responsabilidade de garantiras condições necessárias para que as crianças e adolescentes desenvolvam a melhor qualidade/quantidade de massa óssea...

Efficacy and safety of Menatetrenone-4 postmenopausal Thai women.

Clinical and comparative study of the efficacy and adverse events of Menatetrenone-4. The control group (n=40) received elemental calcium carbonate 800 mg/day and the Menatetrenone-4 treated group received elemental calcium carbonate 800 mg/day plus vitamin K2 45 mg/day (n=43). The vitamin K2 treated group showed a marked decrease of undercarboxylated osteocalcin at 2 weeks, six months (51.52% p=0.0001) and twelve months (87.26% p=0.0001) compared to the calcium treated group. At the end of the sixth and twelve months both groups did not increase bone mass of the hip but the vitamin K2 treated group increased 0.6 per cent of bone mass of the lumbar spine and decreased bone resorption 65.42 per cent (p=0.0001) compared to the calcium treated group. The calcium treated group was switched to the vitamin K2 treated group at the end of six months and showed a decrease of the level of undercarboxylated osteocalcin the same as the former vitamin K2 treated group. The adverse events were 2 cases of mild skin rash which subsided after cessation of medication.

Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients

CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalities in end-stage renal disease (ESRD). OBJECTIVE: To compare the phosphorus binding power and the hypercalcemic effect of calcium acetate and calcium carbonate in hemodialysis patients. TYPE OF STUDY: Crossover, randomized, double-blind study. PLACE: A private hospital dialysis center. PARTICIPANTS: Fifty-two patients who were undergoing regular hemodialysis three times a week ([Ca++] dialysate = 3.5 mEq/L). PROCEDURES: Half of the patients were started on 5.6 g/day of calcium acetate and, after a 2 week washout period, received 6.2 g/day of calcium carbonate. The other half followed an inverse protocol. MAIN MEASUREMENTS: Clinical interviews were conducted 3 times a week to monitor for side effects. Determinations of serum urea, calcium, phosphorus, hematocrit, Kt/V and blood gas analysis were obtained before and after each treatment. RESULTS: Twenty-three patients completed the study. A significant increase in calcium plasma levels was only observed after treatment with calcium carbonate [9.34 mg/dl (SD 0.91) vs. 9.91 mg/dl (SD 0.79), P < 0.01]. The drop in phosphorus levels was substantial and significant for both salts [5.64 mg/dl (SD 1.54) vs. 4.60 mg/dl (SD 1.32), P < 0.01 and 5.89 mg/dl (SD 1.71) vs. 4.56 mg/dl (SD 1.57), P < 0.01, for calcium acetate and calcium carbonate respectively]. The percentage reduction in serum phosphorus (at the end of the study) per milliequivalent of salt administered per day tended to be higher with calcium acetate but statistical significance was not found. CONCLUSION: Calcium acetate can be a good alternative to calcium carbonate in the handling of hyperphosphatemia in ESRD patients. When calcium acetate is used, control of hyperphosphatemia can be achieved with a lower administration of calcium, perhaps with a lower risk of hypercalcemia

Psoríase e pseudo-hipoparatireoidismo / Psoriasis and pseudohypoparathyroidism

Relato de caso clínico de paciente do sexo masculino, de 24 anos de idade, com psoríase pustulosa havia dois meses. Apresentava antecedentes de crises convulsivas e retardo do desenvolvimento neuropsicomotor. Ao exame físico o sinal de Trousseau foi positivo, e a dosagem de cálcio no soro estava acentuadamente diminuída. O diagnóstico foi de psoríase pustulosa generalisada associada a pseudo-hipoparatireoidismo. Inicialmente o paciente foi tratado com etretinato, sem controle do quadro; porém, com detecçäo da hipocalcemia e a reposiçäo do cálcio, houve melhora acentuada das lesöes cutâneas. A remissäo completa foi obtida com a correçäo da hipocalcemia. Esses resultados indicam que a hipocalcemia estava diretamente relacionada com a manutençäo das lesöes de psoríase pustulosa generalizada e pseudo-hipoparatireoidismo